ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 674

Clinical Characteristics of Japanese Patients with Reactive Arthritis Induced By Intravesical BCG Therapy for Bladder Cancer: A 19 Years Two-Center Retrospective Study

Hirofumi Nishikawa1, Yoshinori Taniguchi1, Takashi Karashima2, Tetsushi Aita3, Susumu Nishiyama3, Yasuhiko Yoshinaga3, Yoshitaka Kumon4, Yoshiko Shimamura1, Kosuke Inoue1, Taro Horino1, Taro Shuin2 and Yoshio Terada1, 1Kochi University, Nankoku, Japan, 2Urology, Kochi University, Nankoku, Japan, 3Kurashiki Medical Center, Kurashiki, Japan, 4Chikamori Hospital, Kochi, Japan

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Enthesitis, Infection, reactive arthritis and spondylarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2015

Title: Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment Poster I: Clinical Aspects and Assessments

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

Intravesical instillation of BCG is used as an effective immunotherapy of bladder cancer. However it may have, as adverse event, a reactive arthritis (ReA) and the incidence are known as about 0.5 to 1 %. To evaluate clinical characteristics and incidence of Japanese patients with ReA induced by intravesical BCG therapy (iBCG) for bladder cancer.

Methods: The clinical symptoms, laboratory, and imaging findings of Japanese patients who received iBCG (n=453 (182 and 271 in Kochi University Hospital (KUH) and Kurashiki Medical Center (KMC), respectively)) for bladder cancer from March 1997 to April 2015 (for 19 years) were retrospectively assessed. Especially, the patients with ReA and conjunctivitis/uveitis were examined. All data are presented as mean ± SD.

Results: Of the patients received iBCG (age 71±10 and 69±11; male/female 134/48 and 215/56 in KUH and KMC, respectively), 50/182 (27%) and 35/271 (13%), 51/182 (28%) and 48/271 (18%), and 78/182 (43%) and 73/271 (27%) in KUH and KMC presented fever, hematuria and painful urination, respectively. ReA was revealed in 4/182 (2.2%) and 3/271 (1.1%), uveitis in 3/182 (1.6%) and 1/271 (0.4%), and conjunctivitis in 15/182 (8.2%) and 14/271 (5.2%) in KUH and KMC, respectively. As the total evaluation, ReA was revealed in 7/453 (1.5%). Moreover, most patients with ReA also had hepatic dysfuntion. All ReA were developed after 3-times of iBCG. Clinical, ultrasound and FDG-PET/CT findings of ReA induced by iBCG showed asymmetric polyarthritis/polyenthesitis pattern in shoulder, sternoclavicular joints, spinous process, sacroiliac joints, ischial tuberosity, hip, knee and ankle. Laboratory examinations showed high CRP (>10mg/dl), 25% HLA-B27 positivity (in 1 of 4 cases), 50% HLA-B51 positivity (in 2 of 4 cases). All ReA patients were improved by treatments with prednisolone and isoniazid. 

Conclusion: The incidence of ReA induced by iBCG in Japanese population was 1.5 % and it might be almost equal or more than the incidence, 0.5 to 1 %, in the Western countries from previous reports. Positive HLA-B27 was revealed in 25% of ReA patients as background in our study, suggesting lower frequency than 51 to 55% in the Western countries. Therefore, besides HLA phenotype, a cross reaction between a mycobacterium epitope and an antigen of joint cartilage might be suggested in the pathogenesis of ReA induced by iBCG in Japan.


Disclosure: H. Nishikawa, None; Y. Taniguchi, None; T. Karashima, None; T. Aita, None; S. Nishiyama, None; Y. Yoshinaga, None; Y. Kumon, None; Y. Shimamura, None; K. Inoue, None; T. Horino, None; T. Shuin, None; Y. Terada, None.

To cite this abstract in AMA style:

Nishikawa H, Taniguchi Y, Karashima T, Aita T, Nishiyama S, Yoshinaga Y, Kumon Y, Shimamura Y, Inoue K, Horino T, Shuin T, Terada Y. Clinical Characteristics of Japanese Patients with Reactive Arthritis Induced By Intravesical BCG Therapy for Bladder Cancer: A 19 Years Two-Center Retrospective Study [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/clinical-characteristics-of-japanese-patients-with-reactive-arthritis-induced-by-intravesical-bcg-therapy-for-bladder-cancer-a-19-years-two-center-retrospective-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-characteristics-of-japanese-patients-with-reactive-arthritis-induced-by-intravesical-bcg-therapy-for-bladder-cancer-a-19-years-two-center-retrospective-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology